EASL 2016: Looking For A Competitive Edge In Hepatitis C
This article was originally published in Scrip
Executive Summary
The International Liver Congress hosted by the European Association of the Study of the Liver (EASL) from April 13 to 17 in Barcelona will give hepatitis C drug developers an opportunity to carve out competitive niches before Phase III data for shorter treatment regimens are revealed later in 2016.